KNSA | tickerfilter.com

Fundamental analysis

21%

Profitability 25%

Dept financing 2%

Liquidity 50%

Performance 15%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

2.76%

1 Month

11.01%

3 Months

13.44%

6 Months

32.37%

1 Year

120.99%

2 Year

134.24%

Key data

Stock price

$47.27

P/E Ratio

105.98

DAY RANGE

$43.33 - $47.46

EPS

$0.80

52 WEEK RANGE

$18.26 - $49.12

52 WEEK CHANGE

$122.24

MARKET CAP

6.253 B

YIELD

N/A

SHARES OUTSTANDING

153.071 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

07-22-2025

BETA

0.91

PUBLIC FLOAT

AVERAGE 10 VOLUME

$877,149

AVERAGE 30 VOLUME

$595,072

Company detail

CEO: Sanj K. Patel
Region: US
Website: kiniksa.com
Employees: 220
IPO year: 2018

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Kiniksa Pharmaceuticals, Ltd. focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease. KPL-404 is a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation.

KNSA - Kiniksa Pharmaceuticals International, plc